MR. HUMAYUN DHANRAJGIR has a very rich and varied experience in the pharmaceutical industry. He has held several senior management positions including that of the Vice Chairman & Managing Director of Glaxo India Limited. He was also the Managing Director of Kodak India Ltd. He is a former President of the Organization of Pharmaceutical Producers of India (O.P.P.I) and was a General Committee member of Bombay Chanmber of Commerce and Industry. Mr. Dhanrajgir joined the Board of the Company in September, 2000.

Mr. Dhanrajgir is a graduate in Chemical Engineering from Loughborough University, UK, Member – Institute of Chemical Engineers, UK, Chartered Engineer, UK and has completed the Advanced Management Program of Harvard Business School.

Mr. Dhanrajgir is an independent Non-Executive Director of Cadila Healthcare Limited, HDFC Asset Management Company Limited, Zydus Wellness Limited, Next Gen Publishing Limited, Themis Medicare Ltd among others. He is also a Trustee of Breach Candy Hospital Trust, Mumbai and on the Advisory Board of U.S. Pharmacopeia (India). He is a Member of the Global Advisory Board of Asian Center for Corporate Governance.

MR. S. K. BAPAT has been associated with the Company since February, 1999. He is a highly distinguished and decorated erstwhile officer of the Indian Police Service (IPS), having held senior appointments with the Government of India and the Government of Maharashtra like Joint Director – Intelligence Bureau, Ministry of Home Affairs, Commissioner of Police, Mumbai and Senior Member of the Maharashtra Public Service Commission. He was the President of the Indian chapter of a global philanthropic foundation for seven years. He has special interest in areas relating to National Security, Human Resource Development and Corporate Social Responsibility.

MR. BERJIS DESAI is the Managing Partner of J. Sagar Associates, a national law firm in Mumbai, Delhi, Bangalore, Hyderabad and Dubai. Mr. Desai specialises in mergers and acquisitions, derivatives, corporate and financial laws, international business laws and international commercial arbitration. Mr. Berjis Desai has been on the Board of the Company since 1997.

Mr. Berjis Desai is a law graduate from the Mumbai University and a post-graduate in law from the Cambridge University.

Some of the companies in which Mr. Berjis Desai is a Director are Praj Industries Limited, Sterlite Industries (India) Limited, The Great Eastern Shipping Company Limited and NOCIL Limited.

DR. MAHENDRA PATEL has an all round expertise in the areas of Active Pharmaceutical Ingredients, formulation development, bio-equivalence studies, Intellectual Property and Regulatory Processes. He has the honor of holding 30 patents to his credit. He set up and successfully led his own generic company, Invamed, in the USA, which was later acquired by multinational pharma giant, Sandoz. Dr. Patel has also been associated with large transnational pharma companies in the USA like Bristol Myers Squibb and Lederle where he held senior management positions in R&D. Dr. Patel joined the Company as a Director in January, 2005.

Dr. Patel is a Ph.D. in Pharmaceutical Science from University of Wisconsin, USA. Dr. Patel is also on the Board of Zydus Pharmaceuticals USA, Inc.

MR. AKHIL GUPTA represents the Blackstone Group on the Board of the Company. Mr. Gupta is the Chairman and Managing Director of Blackstone Advisors India Private Limited. Prior to Blackstone, he has worked as CEO – Corporate Development for Reliance Industries Limited and Reliance Infocomm Limited. He has held senior positions in various organizations in the USA. He has more than 30 years of experience in the corporate world. Mr. Gupta became the member of the Board of the Company in August, 2006.

Mr. Gupta is a B. Tech in Chemical Engineering from IIT, Delhi and MBA from Stanford University, USA.

MR. MARVIN SAMSON received a Bachelor of Science degree in Chemistry from Temple University. He has been the founder of several organizations in USA e.g. Samson Medical Technologies, Elkins-Sinn, Marsam Pharmaceuticals, etc.

Mr. Samson holds five U.S. patents pertaining to pharmaceutical manufacturing. Apart from Emcure, he is a director on the Boards of Baxa Corporation, Flynn Pharma and Dobfar Holdings S.p.A. He is the Chairman of the Board of Qualitest Pharmaceuticals.

A recipient of various awards for business leadership, Mr. Samson continues to be actively involved in philanthropic activities.

MR. SATISH MEHTA is the Chief Executive Officer and Managing Director and founder member of the Company. He has vast experience in the pharmaceutical industry. He is the prime mover for various strategic alliances and growth plans of the Company. His dynamic leadership has led the Company to become a major player in the pharmaceutical industry.

Mr. Satish Mehta is a Post Graduate in Chemistry and MBA from IIM, Ahmedabad.

MR. ARUNKUMAR KHANNA is the Chief Operating Officer and Executive Director of the Company and heads the operations of the Company. He has over 35 years of rich and varied experience in leading pharma companies.

Since 1995, Mr. Khanna has played a pivotal role in transforming Emcure into the fastest growing Pharma Major. He has also been instrumental in ensuring the wide global reach of Emcure's leading brands. Emcure's Corporate Social Responsibility in the area of HIV / AIDS has been widely acclaimed and appreciated as a result of his passionate efforts.

MR. MAHESH SHAH is post graduate in Organic Chemistry with total experience of 32 years. Mr. Shah is the Director (Technical) and is associated with Emcure since its inception. He is in charge of manufacturing operations of all the formulation plants. He has played lead role in getting regulatory approvals from USFDA for solid dosage, sterile dosage and bulk drug manufacturing facilities besides regulatory approvals from UKMHRA, WHO GENEVA and MCC South Africa for Hinjwadi solid dosage facility. He is also involved in various projects that the organization has undertaken at Hinjwadi and Jammu.

DR. MUKUND GURJAR is the Chief Scientific Officer and a member of the Board of the Company. He has over 30 years of experience in pharmaceutical sciences and has spearheaded major projects in drugs and pharmaceuticals. He is a fellow at various National and International Academies. He has contributed significantly in synthetic organic chemistry involving both basic and applied research. Over 50 Ph D students were trained under his supervision and he has published more than 200 papers in various international journals. He is a Regional Editor of Synthetic Communication, an international journals published by Taylor & Francis, USA and also member of the Editorial Board of Organic Process Research & Development of American Chemical society and Indian Journal of Chemistry of CSIR, New Delhi. Dr. Gurjar is on the Board of the Company since 2001.

Dr. Gurjar has obtained Master of Science degree in Organic Chemistry and Ph.D. in chemistry from the Nagpur University. He also obtained the second Ph.D. degree from the London University, UK.